Biocon's profit struggles continue in Q3; net profit plunges 96%

Jan 31, 2025  · Biocon's profit struggles continue in Q3; net profit plunges 96% On a year-on-year basis, the company’s total revenue has contracted by 15 per cent to ₹3,856 crore from ₹4,519 …


Install CouponFollow Chrome Extension   CouponFollow Extension

96%
OFF

Biocon's Profit Struggles Continue In Q3; Net Profit Plunges 96%

2 weeks from now

Jan 31, 2025  · Biocon's profit struggles continue in Q3; net profit plunges 96% On a year-on-year basis, the company’s total revenue has contracted by 15 per cent to ₹3,856 crore from ₹4,519 …

indiatimes.com

96%
OFF

Biocon Q3 Results: Profit Plummets 96%; Misses Estimates

2 weeks from now

Jan 30, 2025  · Biocon Ltd.'s Q3FY25 consolidated net profit plummeted 96% to Rs 25 crore, falling short of analysts' estimates. Revenue declined 3.4% to Rs 3,821 crore. Biocon Ltd.'s …

ndtvprofit.com

96%
OFF

Biocon Q3 Results: PAT Plunges 96% To ₹25 Cr; Revenue Up 7%

2 weeks from now

Jan 30, 2025  · Bengaluru-based Biocon Ltd recorded a profit after tax (PAT) of ₹25 crore for the quarter ended December 31, a 96% decline compared to ₹660 crore in the same quarter last …

thehindubusinessline.com

2%
OFF

Biocon Share Price Rises Despite Bleak Q3 Earnings

2 weeks from now

Jan 31, 2025  · Biocon Ltd. share price rose despite bleak third quarter performance. The company's consolidated net profit plunged 96.2% to Rs 25.1 crore from Rs 660 crore. Biocon's …

ndtvprofit.com

50%
OFF

Biocon Q3FY24 Revenue At Rs 4,519 Cr, Up 50%; Biosimilars Up …

2 weeks from now

Feb 8, 2024  · Net R&D investments for the quarter were Rs 329 crore, representing 11% of revenue ex-Syngene. Core EBITDA at Rs 983 crore, represents core operating margins of …

biocon.com

96%
OFF

Biocon Shares In Focus After Q3 PAT Drops 96% YoY, 1.5

2 weeks from now

Jan 31, 2025  · Biocon reported a 96% year-on-year (YoY) drop in net profit to Rs 25 crore in Q3FY25. The company had reported a net profit of Rs 660 crore during Q3FY24, aided by an …

indiatimes.com

36%
OFF

Biocon Q3FY23 Revenue At Rs 3,020 Cr, Up 36%; Biosimilars Up …

2 weeks from now

Feb 14, 2023  · EBITDA at Rs 723 Cr, Up 35%; Core EBITDA at Rs 1,069 Cr, Up 49%; Net Profit (excluding exceptional items) at Rs 140 Cr Bengaluru, Karnataka, India: February 14, 2023: …

biocon.com

15%
OFF

Biocon Quarterly Results, Biocon Financial Statement & Accounts

2 weeks from now

Net Profit/(Loss) For the Period: 584.00: 3.20: 0.90: 14.00: ... Lupin Q3 profit seen up 15% to Rs 609cr, US biz may lift revenue ... Low earnings for Lupin to continue for next 2 qtrs: IIFL ...

moneycontrol.com

9%
OFF

Biocon's Q3 Revenue Dips; Banks On Obesity Drugs For Future Growth

2 weeks from now

Jan 30, 2025  · Revenue from Biocon's biosimilars business, its largest, fell 7.9% to 22.9 billion rupees. Biosimilars are copies of high-priced drugs used to treat illnesses such as rheumatoid …

yahoo.com

4%
OFF

Biocon Shares Up 4% Despite Sharp Fall In Profit, Find Out Why?

2 weeks from now

Jan 31, 2025  · The share price of Biocon rose almost 4% to an intra-day high of Rs 370.90 despite reporting a fall of 96.2% year-on-year in the third quarter of FY25. The company …

financialexpress.com

4%
OFF

Here's Why Biocon Share Price Gained 4% Despite Fall In Profits In Q3

2 weeks from now

Jan 31, 2025  · Here's why Biocon share price gained 4% despite fall in profits in Q3 ... The pharma company’s Q3FY25 consolidated net profit dropped to Rs 25.1 crore, compared to Rs …

business-standard.com

9%
OFF

Biocon's Q3 Financial Results Show Decline In Profitability And Cash …

2 weeks from now

Nov 2, 2024  · This trend is expected to continue in the near term. Similarly, the Profit After Tax (PAT) has also seen a significant decline of 105.9% to Rs -23.16 crore compared to the …

marketsmojo.com

10%
OFF

Biocon’s Net Profit Declines 10% To Rs 168 Crore In Q2FY23; …

2 weeks from now

Nov 14, 2022  · The drugmaker reported a 10 per cent dip in net profit for Q2FY23 to Rs 168 crore on account of tax adjustments. ... Infosys Q3 Results Highlights: Profit rises by 11.46% YoY to …

financialexpress.com

46%
OFF

Biocon's Q3 Profit Plunges 46% To Rs 92 Crore - Times Of India

2 weeks from now

Jan 24, 2018  · The Bengaluru-based firm’s net profit fell 46% to Rs 92 crore in the December quarter compared to Rs 171 crore in the year-ago period. Its revenue was flat at Rs 1,092 crore.

indiatimes.com

FAQs about Biocon's profit struggles continue in Q3; net profit plunges 96% Coupon?

What was Biocon's net profit in q3fy25?

Bengaluru-based biopharma firm Biocon on Thursday reported a consolidated net profit of Rs 25.1 crore in the third quarter of the financial year 2024-25 (Q3FY25). During the same period in the previous financial year, the company reported a loss of Rs 16 crore. ...

How did Biocon share price perform in q3fy24?

Biocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 crore in Q3FY25. In comparison, the company had posted a net profit of Rs 660 crore in Q3FY24, boosted by an exceptional item of Rs 566 crore. ...

Will Biocon stock remain in focus after Q3 results?

The shares of Biocon will remain in focus on Friday after the company reported its Q3 results for FY25, posting a decline of 96% YoY in its net profit at Rs 25 crore, and also announced the acquisition of an additional 1.5% equity stake in its subsidiary Biocon Biologics. ...

How did Biocon perform in Q3 fy25?

Adjusting for these factors, Biocon’s Q3 FY25 revenue saw a 10 per cent year-on-year growth. The company’s net research and development investments for the quarter stood at Rs 199 crore, representing 7 per cent of revenue excluding Syngene. Moreover, Biocon’s biosimilars segment grew 14 per cent Y-o-Y to Rs 2,289 crore. ...

Why did Biocon raise funds?

We reported a strong EBITDA growth of 35% to Rs 723 crore, representing a healthy EBITDA margin of 24%. Core EBITDA grew 49% to Rs 1,069 crore. As a part of our strategy to reduce the acquisition debt, Biocon has raised funds through a partial divestment of its stake in Syngene. ...

Why did Biocon biologics gain Rs 350 crore?

This growth was supported by income from the divesture of two non-core business assets of Biocon Biologics’ Branded Formulations India business amounting to Rs 350 crore and a gain of Rs 456 crore from Biocon’s stake dilution in Bicara Therapeutics. ...

Install CouponFollow Extension on Chrome

Install the CouponFollow extension to search for discount codes when shopping the fastest!

Install CouponFollow Chrome Extension   Install CouponFollow Chrome Extension